Log in
Enquire now
‌

US Patent 11958902 Anti-TIGIT antibodies

Patent 11958902 was granted and assigned to Merck Sharp & Dohme Limited on April, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Merck Sharp & Dohme Limited
Merck Sharp & Dohme Limited
0
Current Assignee
Merck Sharp & Dohme Limited
Merck Sharp & Dohme Limited
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119589020
Patent Inventor Names
Linda Liang0
Wolfgang Seghezzi0
Laurence Fayadat-Dilman0
Veronica Juan0
Sybil M. G. Williams0
Date of Patent
April 16, 2024
0
Patent Application Number
169398830
Date Filed
July 27, 2020
0
Patent Citations
‌
US Patent 8968750 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other C2-domain containing proteins
0
‌
US Patent 7193069 Full-length cDNA
0
‌
US Patent 7368527 HADDE71 polypeptides
0
‌
US Patent 10766957 Anti-TIGIT antibodies
0
Patent Primary Examiner
‌
Lynn A Bristol
0
CPC Code
‌
C07K 16/2803
0
‌
C07K 2317/24
0
Patent abstract

The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11958902 Anti-TIGIT antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.